17 Mar 2017 10:33 pm
The other shoe drops.Misty » 11 Mar 2017 3:15 pm » wrote:
On November 30th, 2016, Preet Bharara was called to Trump Tower and asked by the incoming POTUS and his incoming AG if would stay on in his job as the U.S. Attorney for the Southern District of NY.
Yesterday he was asked to resign.
He refused to resign and was fired today.
Price lied about his stock deals under oath in his confirmation hearing.Bharara was investigating Trump cabinet member when fired: report
Former U.S. Attorney Preet Bharara was investigating a top member of President Trump’s cabinet when he was fired, according to a report Friday.
Bharara, asked along with 45 other prosecutors to resign last week, was overseeing a probe into stock trades made by Health & Human Services Secretary Tom Price, ProPublica reported.
In December, the Wall Street Journal reported Price traded more than $300,000 worth of shares in health companies over a recent four-year period.
At the time he was taking actions in Congress that could have affected those companies.
One Democrat called on the Georgia lawmaker to be investigated by the Securities and Exchange Commission.
“The fact that these trades were made and in many cases timed to achieve significant earnings or avoid losses would lead a reasonable person to question whether the transactions were triggered by insider knowledge,” Rep. Louise Slaughter, who represents Rochester, wrote at the time.
Rep. Tom Price Got Privileged, Discounted Offer on Biomedical Stock, Company Says
Rep. Tom Price got a privileged offer to buy a biomedical stock at a discount, the company’s officials said, contrary to his congressional testimony this month.
The Georgia Republican tapped by President Donald Trump to be secretary of the Department of Health and Human Services testified in his Senate confirmation hearings on Jan. 18 and 24 that the discounted shares he bought in Innate Immunotherapeutics Ltd., an Australian medical biotechnology company, “were available to every single individual that was an investor at the time.”
In fact, the cabinet nominee was one of fewer than 20 U.S. investors who were invited last year to buy discounted shares of the company -- an opportunity that, for Price, arose from an invitation from a company director and fellow congressmen.
The shares were discounted 12% off the traded price in mid-June only for investors who participated in a private placement arranged to raise money to complete a clinical trial. The company’s shares have tripled since the offering.